Glaukos (GKOS) vs Medline (MDLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Medline is the larger company by market cap ($48.75 billion vs $14.05 billion), about 3.5 times the size. On valuation, Medline trades at a lower forward P/E (24.0x vs 169.5x for Glaukos). Medline converts more of its revenue into profit, with a net margin of 4.1% versus -37.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GKOS | MDLN |
|---|---|---|
| Share price | $237.31 | $37.04 |
| Market cap | $14.05B | $48.75B |
| 1-day change | -0.33% | -2.11% |
| YTD return | +110.18% | -11.81% |
| 1-year return | +138.22% | — |
| 5-year return | +421.56% | — |
| P/E ratio (TTM) | — | 84.18 |
| Forward P/E | 169.50 | 23.98 |
| EPS (TTM) | $-2.95 | $0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $507.44M | $28.43B |
| Revenue growth (YoY) | +32.33% | — |
| Net income (latest FY) | $-187.69M | $1.16B |
| Gross margin | 55.72% | 26.44% |
| Operating margin | -39.33% | 7.78% |
| Net margin | -36.99% | 4.08% |
| 52-week high | $255.19 | $50.88 |
| 52-week low | $93.96 | $31.37 |
| Distance from 52-week high | -7.00% | -27.20% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +2.76% | +23.52% |
| Average volume | 1.19M | 9.55M |
| Shares outstanding | 59.20M | 878.66M |
| Employees | 1,094 | 45,000 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Medline is about 3.5 times larger than Glaukos by market value ($48.75B vs $14.05B).
- Medline is more profitable, keeping 4.1 cents of every revenue dollar as net income versus -37.0 cents for Glaukos.
About Glaukos
GKOS stock →Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.
Health Care · Medical/Dental Instruments · 1,094 employees
About Medline
MDLN stock →Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally.
Health Care · Medical/Dental Instruments · 45,000 employees
GKOS vs MDLN FAQ
Which is bigger, Glaukos or Medline?
Medline (MDLN) is larger, with a market capitalization of $48.75B compared with $14.05B for Glaukos (GKOS).
Are Glaukos and Medline in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.